Melanoma Clinical Trial

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Summary

This is an observational study that includes patients with melanoma who will be treated with adjuvant immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

≥18 years of age
Diagnosis of Melanoma and planned to undergo adjuvant therapy with immune checkpoint inhibitors.
Able to provide written informed consent

Exclusion Criteria:

Pregnant or breast-feeding:
Prior treatment with ICI therapy.
Vulnerable patients, including pregnant women and prisoners
Absolute Contraindication to rest/vasodilator stress PET/CT

Study is for people with:

Melanoma

Estimated Enrollment:

25

Study ID:

NCT06332131

Recruitment Status:

Not yet recruiting

Sponsor:

Abramson Cancer Center at Penn Medicine

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Abramson Cancer Center at University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

25

Study ID:

NCT06332131

Recruitment Status:

Not yet recruiting

Sponsor:


Abramson Cancer Center at Penn Medicine

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.